2．成人領域
肺炎球菌は小児の20～40%，成人の5～10%が保菌しており，肺炎や髄膜炎などの重篤な疾患を引き起こす．また，インフルエンザに二次感染することで重症化することが明らかとなっている．肺炎球菌感染症の予防のために，小児には7価肺炎球菌蛋白結合型ワクチン（PCV7）（2013年11月からは13価肺炎球菌蛋白結合型ワクチン（PCV13）），成人には23価肺炎球菌莢膜多糖体型ワクチン（PPV23）の接種が推奨されているが，米国では2000年に小児へPCV7が導入されて以来，集団免疫効果により小児だけでなく高齢者でも侵襲性肺炎球菌感染症（IPD）と肺炎が減少している．現在，他の先進国と比べて，日本のインフ...
Saved in:
| Published in | 日本内科学会雑誌 Vol. 102; no. 11; pp. 2936 - 2944 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本内科学会
2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-5384 1883-2083 |
| DOI | 10.2169/naika.102.2936 |
Cover
| Abstract | 肺炎球菌は小児の20～40%，成人の5～10%が保菌しており，肺炎や髄膜炎などの重篤な疾患を引き起こす．また，インフルエンザに二次感染することで重症化することが明らかとなっている．肺炎球菌感染症の予防のために，小児には7価肺炎球菌蛋白結合型ワクチン（PCV7）（2013年11月からは13価肺炎球菌蛋白結合型ワクチン（PCV13）），成人には23価肺炎球菌莢膜多糖体型ワクチン（PPV23）の接種が推奨されているが，米国では2000年に小児へPCV7が導入されて以来，集団免疫効果により小児だけでなく高齢者でも侵襲性肺炎球菌感染症（IPD）と肺炎が減少している．現在，他の先進国と比べて，日本のインフルエンザワクチンと肺炎球菌ワクチンの接種率は低い水準にあり，今後は両ワクチンの接種率を向上する必要がある． |
|---|---|
| AbstractList | 肺炎球菌は小児の20～40%，成人の5～10%が保菌しており，肺炎や髄膜炎などの重篤な疾患を引き起こす．また，インフルエンザに二次感染することで重症化することが明らかとなっている．肺炎球菌感染症の予防のために，小児には7価肺炎球菌蛋白結合型ワクチン（PCV7）（2013年11月からは13価肺炎球菌蛋白結合型ワクチン（PCV13）），成人には23価肺炎球菌莢膜多糖体型ワクチン（PPV23）の接種が推奨されているが，米国では2000年に小児へPCV7が導入されて以来，集団免疫効果により小児だけでなく高齢者でも侵襲性肺炎球菌感染症（IPD）と肺炎が減少している．現在，他の先進国と比べて，日本のインフルエンザワクチンと肺炎球菌ワクチンの接種率は低い水準にあり，今後は両ワクチンの接種率を向上する必要がある． |
| Author | 丸山, 貴也 |
| Author_xml | – sequence: 1 fullname: 丸山, 貴也 organization: 国立病院機構三重病院呼吸器内科 |
| BookMark | eNo9z7tKxEAUxvFBVjCuC1a-ReKZOXNLKcHLwoKN1sPJXDRxjZJs4xtYiaXd-hyLj6OCla-grmL1Lz744LfNRt1NFxnb41AIrsv9jporKjiIQpSoN1jGrcVcgMURywAEzxVaucUmw9DUIFEry1FmbFd8vjy83z--rlYfz09vy-UO20w0H-Lkr2N2fnR4Vp3ks9PjaXUwy1shDORahZRqk7zHUtpYJyVDsDxi8FojRakiCWOSsAYDGasDhAhlimRUBA04ZtXvbzss6CK62765pv7OUb9o_Dy6Nch9gxzn6_y4_ld_Sb1rCb8An8BN6Q |
| ContentType | Journal Article |
| Copyright | 2013 一般社団法人 日本内科学会 |
| Copyright_xml | – notice: 2013 一般社団法人 日本内科学会 |
| DOI | 10.2169/naika.102.2936 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1883-2083 |
| EndPage | 2944 |
| ExternalDocumentID | article_naika_102_11_102_2936_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS DIK F5P JSF OK1 RJT |
| ID | FETCH-LOGICAL-j2270-65dffb7fcc3948ebf54dd81e3dc663ae45ea277f2873da786d0de09fea75e0603 |
| ISSN | 0021-5384 |
| IngestDate | Wed Sep 03 06:30:13 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 11 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j2270-65dffb7fcc3948ebf54dd81e3dc663ae45ea277f2873da786d0de09fea75e0603 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/naika/102/11/102_2936/_article/-char/ja |
| PageCount | 9 |
| ParticipantIDs | jstage_primary_article_naika_102_11_102_2936_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20130000 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – year: 2013 text: 20130000 |
| PublicationDecade | 2010 |
| PublicationTitle | 日本内科学会雑誌 |
| PublicationTitleAlternate | 日内会誌 |
| PublicationYear | 2013 |
| Publisher | 一般社団法人 日本内科学会 |
| Publisher_xml | – name: 一般社団法人 日本内科学会 |
| References | 14) Centers for Disease Control and Prevention (CDC): Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) -United States, May-August 2009. MMWR 58 (38): 1071-1074, 2009. 26) Centers for Disease Control and Prevention (CDC): Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 61 (40): 816-819, 2012. 28) Hak E, et al: Rationale and design of CAPITA: a RCT of 13-valent conjugatedpneumococcal vaccine efficacy among older adults. Neth J Med 66 (9): 378-383, 2008. 8) 生方公子, 他: 日本医師会雑誌 138 (4): 715-718, 2009. 18) Christenson B, et al: Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 23: 363-368, 2004. 27) Paradiso PR: Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis 55 (2): 259-264, 2012. 13) Morens DM, et al: Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 198 (7): 962-970, 2008. 3) Bridges CB, et al: Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 284 (13): 1655-1663, 2000. 10) Bewick T, et al: Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 67 (6): 540-545, 2012. 19) Hung IF: Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 51 (9): 1007-1016, 2010. 4) Nichol KL, et al: The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 333 (14): 889-893, 1995. 11) Jackson LA, et al: Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281 (3): 243-248, 1999. 2) Mullooly JP, et al: Influenza- and RSV-associated hospitalizations among adults. Vaccine 25: 846-855, 2007. 20) Chiba H, et al: Benefits of pneumococcal vaccination for bedridden patients. J Am Geriatr Soc 52 (8): 1410, 2004. 24) Pilishvili T, et al: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201 (1): 32-41, 2010. 25) Griffin MR, et al: U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 369 (2): 155-163, 2013. 22) Maruyama T, et al: 23-valent pneumococcal polysaccharide vaccine prevents pneumonia and improves survival in nursing home residents. -A double blind, randomized and placebo controlled trial-. BMJ 340: c1004, 2010. 6) Govaert TM, et al: The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272 (21): 1661-1665, 1994. 12) Mufson MA, et al: Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 9 (6): 403-407, 1991. 7) Hayward AC, et al: Effectiveness of an influenza vaccine program for care home staff to prevent death, morbidity, and health service use among residents: cluster randomized controlled trial. BMJ 333: 1241, 2006. 1) Thompson WW, et al: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186, 2003. 15) Cillóniz C, et al: Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. J Infect 65 (3): 223-230, 2012. 9) Pride MW, et al: Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine. Clin Vaccine Immunol 19 (8): 1131-1141, 2012. 21) Kawakami K, et al: Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28 (43): 7063-7069, 2010. 23) 第16回厚生科学審議会感染症分科会予防接種部会: ワクチン評価に関する小委員会 報告書. 2011. 5) Jefferson TO, et al: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev (2): CD001269, 2007. 17) Brundage JF: Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 6 (5): 303-312, 2006. 16) Maruyama T, et al: A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. Respir Med 102 (9): 1287-1295, 2008. |
| References_xml | – reference: 7) Hayward AC, et al: Effectiveness of an influenza vaccine program for care home staff to prevent death, morbidity, and health service use among residents: cluster randomized controlled trial. BMJ 333: 1241, 2006. – reference: 4) Nichol KL, et al: The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 333 (14): 889-893, 1995. – reference: 9) Pride MW, et al: Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine. Clin Vaccine Immunol 19 (8): 1131-1141, 2012. – reference: 8) 生方公子, 他: 日本医師会雑誌 138 (4): 715-718, 2009. – reference: 3) Bridges CB, et al: Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 284 (13): 1655-1663, 2000. – reference: 16) Maruyama T, et al: A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. Respir Med 102 (9): 1287-1295, 2008. – reference: 21) Kawakami K, et al: Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28 (43): 7063-7069, 2010. – reference: 27) Paradiso PR: Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis 55 (2): 259-264, 2012. – reference: 26) Centers for Disease Control and Prevention (CDC): Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 61 (40): 816-819, 2012. – reference: 14) Centers for Disease Control and Prevention (CDC): Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) -United States, May-August 2009. MMWR 58 (38): 1071-1074, 2009. – reference: 20) Chiba H, et al: Benefits of pneumococcal vaccination for bedridden patients. J Am Geriatr Soc 52 (8): 1410, 2004. – reference: 12) Mufson MA, et al: Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 9 (6): 403-407, 1991. – reference: 22) Maruyama T, et al: 23-valent pneumococcal polysaccharide vaccine prevents pneumonia and improves survival in nursing home residents. -A double blind, randomized and placebo controlled trial-. BMJ 340: c1004, 2010. – reference: 19) Hung IF: Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 51 (9): 1007-1016, 2010. – reference: 1) Thompson WW, et al: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186, 2003. – reference: 10) Bewick T, et al: Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 67 (6): 540-545, 2012. – reference: 24) Pilishvili T, et al: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201 (1): 32-41, 2010. – reference: 15) Cillóniz C, et al: Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. J Infect 65 (3): 223-230, 2012. – reference: 5) Jefferson TO, et al: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev (2): CD001269, 2007. – reference: 6) Govaert TM, et al: The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272 (21): 1661-1665, 1994. – reference: 25) Griffin MR, et al: U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 369 (2): 155-163, 2013. – reference: 17) Brundage JF: Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 6 (5): 303-312, 2006. – reference: 18) Christenson B, et al: Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 23: 363-368, 2004. – reference: 23) 第16回厚生科学審議会感染症分科会予防接種部会: ワクチン評価に関する小委員会 報告書. 2011. – reference: 13) Morens DM, et al: Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 198 (7): 962-970, 2008. – reference: 2) Mullooly JP, et al: Influenza- and RSV-associated hospitalizations among adults. Vaccine 25: 846-855, 2007. – reference: 28) Hak E, et al: Rationale and design of CAPITA: a RCT of 13-valent conjugatedpneumococcal vaccine efficacy among older adults. Neth J Med 66 (9): 378-383, 2008. – reference: 11) Jackson LA, et al: Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281 (3): 243-248, 1999. |
| SSID | ssib043658134 ssj0066765 ssib002821954 ssib005879745 ssib007485360 ssib058493862 ssib000940260 ssib002484664 |
| Score | 1.9190632 |
| Snippet | ... |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 2936 |
| SubjectTerms | インフルエンザワクチン 医療経済効果 肺炎球菌ワクチン 肺炎球菌性肺炎 高齢者肺炎 |
| Title | 2．成人領域 |
| URI | https://www.jstage.jst.go.jp/article/naika/102/11/102_2936/_article/-char/ja |
| Volume | 102 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本内科学会雑誌, 2013/11/10, Vol.102(11), pp.2936-2944 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NihQxEA7DCuLFf_GfPVgn6TV_3UnAS_fYw6KsIOzC3pruTvowh1Fk9uITeBKP3tbnWHwHX0IFT76CVememV7x4K4QuptKVUh1heSrkKow9ki2xtUe3VTK9Z3oDv2UxrcyEVkjGt4QZqfg5L2X2e6Bfn6YHk4mX0enlo6WzU777q9xJeexKtLQrhQlewbLrhtFAn6jffGJFsbnP9lYQjmDYgq2hDIDa8FxKDUUOZXSQc7BWShTcDMsYxxK_M5AnsaPKeRTYrPYCFKQbsAJouTPIM9im1NwsU1XxCoLeQ52vcUaWSwVFCoEFbQdsRUSCh2r3aoPwyZDHx0aB8QgbjlJoB7UHewFEsvY_QJyRT0tFLh0reLj82kxnqilSHAu7vcaQj83W6vQ_P29N-vJm8vxKBXjudipbLSuS9cnmvxzzZAio5SrC4rYokQWOxu5U3m4BytXkbFCRnSe4ov4q1UtxcpVcwTsF6Qxgs6Yvng1wrtOUw63ET6yp9L7o_8rxvn5Umvc-DoCoxFdbeS1QvwoNvn9EEw6ZbN1_jQ6v9xf4TH8zT5rKWn85LS-iL_m6I2sTjJGcLV_lV0evKLtvFfvGpvM6-vs4t5w7uMGuyJ_ffnw4_3HbycnPz9_-n58fJMdzMr96W4y3OWRzKU0PMlS33WN6dpWOW1D06XaeyuC8i1i3jroNNT4xzp04JWvjc0894G7LtQmDTzj6hbbWrxehNtsW_lg2g5hf8O9roVrUtVKUyvfceVxvbzDnva6VG_6hC3VmUx39__E77FLMt6YQrt099nW8u1ReIC4ddk8jGPhN4Pkbs8 |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=2%EF%BC%8E%E6%88%90%E4%BA%BA%E9%A0%98%E5%9F%9F&rft.jtitle=%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A%E9%9B%91%E8%AA%8C&rft.au=%E4%B8%B8%E5%B1%B1%2C+%E8%B2%B4%E4%B9%9F&rft.date=2013&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A&rft.issn=0021-5384&rft.eissn=1883-2083&rft.volume=102&rft.issue=11&rft.spage=2936&rft.epage=2944&rft_id=info:doi/10.2169%2Fnaika.102.2936&rft.externalDocID=article_naika_102_11_102_2936_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-5384&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-5384&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-5384&client=summon |